Bukwang Pharmaceutical Co., Ltd.
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various t…
Drug Manufacturers - Specialty & Generic
KR, Seoul [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q1 | Q3 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -51.76 | 111.55 | -231.23 | |
| Graham Fair Price | -78.29 | 361.03 | 1662.78 | |
| PEG | 936.23 | -6.10 | 0.59 | |
| Price/Book | -14.21 | 1.75 | 2.04 | |
| Price/Cash Flow | 25.51 | 49.39 | 39.35 | |
| Prices/Earnings | 1311.73 | 633.75 | -44.89 | |
| Price/Sales | -30.93 | 9.22 | 13.36 | |
| Price/FCF | 25.51 | 49.39 | 39.35 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q1 | Q3 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 109.06 | 1.00 | 0.48 | |
| Operating Margin | 57.66 | 0.07 | -0.05 | |
| ROA | -92.66 | < 0.005 | < 0.005 | |
| ROE | -0.01 | < 0.005 | -93.92 | |
| ROIC | < 0.005 | < 0.005 | -88.08 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q1 | Q3 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | < 0.005 | 111.94 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.90 | 2.25 | 150.75 | |
| EPS QOQ | 0.76 | 1.04 | 36.24 | |
| FCF QOQ | -0.29 | 11.65 | 3983.03 | |
| Revenue QOQ | 0.37 | 0.16 | -58.20 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q1 | Q3 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 263.80 | 0.00 | inf | |
| Days Sales Outstanding (DSO) | 85.81 | 0.00 | inf | |
| Inventory Turnover | 0.34 | 0.00 | inf | |
| Debt/Capitalization | 0.26 | 0.26 | 0.13 | |
| Quick Ratio | 2.12 | 5.22 | 146.50 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q1 | Q3 | Δ in % | |
|---|---|---|---|---|
| Book Value | 3288.45 | 2954.46 | -10.16 | |
| Cash | 2373.24 | 1517.40 | -36.06 | |
| Capex | -0.66 | 14.30 | 2051.78 | |
| Free Cash Flow | 170.53 | 102.66 | -39.80 | |
| Revenue | 502.42 | 549.64 | 9.40 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad